SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
SurModics (SRDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $0.27 per share a year ago.
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.07 per share a year ago.
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System
Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now
SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.
